{"id":"epalrestat-mecobalamin","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Gastrointestinal disturbance"},{"rate":null,"effect":"Injection site reaction"}]},"_chembl":{"chemblId":"CHEMBL2359370","moleculeType":"Small molecule","molecularWeight":"1344.40"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Epalrestat acts as a prostacyclic acid derivative that reduces platelet aggregation, increases blood flow, and protects against ischemic injury in peripheral nerves. Mecobalamin is an active form of vitamin B12 that facilitates methylation reactions and supports neuronal metabolism, myelin synthesis, and nerve regeneration. Together, they are used to improve microcirculation and promote nerve recovery in peripheral neuropathies.","oneSentence":"Epalrestat is a prostacyclin analog that inhibits platelet aggregation and improves microcirculation, while mecobalamin is a cobalamin derivative that supports nerve function and myelin formation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:42:18.288Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute ischemic stroke"},{"name":"Peripheral neuropathy"},{"name":"Diabetic neuropathy"}]},"trialDetails":[{"nctId":"NCT06330233","phase":"NA","title":"Different Amounts of Moxibustion in the Treatment of DPN: A Clinical RCT Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Zhejiang Chinese Medical University","startDate":"2024-09-01","conditions":"Diabetic Peripheral Neuropathy, Pain, Moxibustion","enrollment":90},{"nctId":"NCT05184049","phase":"PHASE4","title":"Effects of Epalrestat on Peripheral Neuropathy and Central Nervous System in Diabetic Patients","status":"UNKNOWN","sponsor":"Xiangya Hospital of Central South University","startDate":"2022-01","conditions":"Diabetes","enrollment":72}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Epalrestat,Mecobalamin","genericName":"Epalrestat,Mecobalamin","companyName":"Xiangya Hospital of Central South University","companyId":"xiangya-hospital-of-central-south-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Epalrestat is a prostacyclin analog that inhibits platelet aggregation and improves microcirculation, while mecobalamin is a cobalamin derivative that supports nerve function and myelin formation. Used for Acute ischemic stroke, Peripheral neuropathy, Diabetic neuropathy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}